Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

iBio (IBIO) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for iBio (IBIO) over the last 17 years, with Q4 2025 value amounting to $99.1 million.

  • iBio's Shares Outstanding (Weighted Average) rose 98555.63% to $99.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $99.1 million, marking a year-over-year increase of 98555.63%. This contributed to the annual value of $10.5 million for FY2025, which is 17405.38% up from last year.
  • As of Q4 2025, iBio's Shares Outstanding (Weighted Average) stood at $99.1 million, which was up 98555.63% from $53.0 million recorded in Q3 2025.
  • iBio's Shares Outstanding (Weighted Average)'s 5-year high stood at $215.5 million during Q1 2021, with a 5-year trough of $490000.0 in Q4 2022.
  • Over the past 5 years, iBio's median Shares Outstanding (Weighted Average) value was $8.7 million (recorded in 2021), while the average stood at $23.5 million.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first skyrocketed by 26960356.75% in 2021, then tumbled by 9595.48% in 2022.
  • Quarter analysis of 5 years shows iBio's Shares Outstanding (Weighted Average) stood at $8.7 million in 2021, then plummeted by 94.38% to $490000.0 in 2022, then skyrocketed by 278.78% to $1.9 million in 2023, then surged by 392.03% to $9.1 million in 2024, then surged by 985.56% to $99.1 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $99.1 million in Q4 2025, compared to $53.0 million in Q3 2025 and $10.5 million in Q2 2025.